AgomAb Therapeutics NV (AGMB) SEC filings
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.97−0.39 (-6.13%)
Close on Nov 16, 2026Market cap $149.25KP/E –Yield –
SEC filings
12 of AgomAb Therapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 6-K | Oct 13, 2026 | Oct 13, 2026 | SEC EDGAR |
| Current report | 6-K | Oct 1, 2026 | Oct 1, 2026 | SEC EDGAR |
| Current report | 6-K | Sep 14, 2026 | Sep 14, 2026 | SEC EDGAR |
| Current report | 6-K | Sep 11, 2026 | Sep 11, 2026 | SEC EDGAR |
| Current report | 6-K | Aug 10, 2026 | Aug 10, 2026 | SEC EDGAR |
| Current report | 6-K | Aug 6, 2026 | Aug 6, 2026 | SEC EDGAR |
| Current report | 6-K | Jun 23, 2026 | Jun 23, 2026 | SEC EDGAR |
| Current report | 6-K | May 27, 2026 | May 27, 2026 | SEC EDGAR |
| Current report | 6-K | Apr 24, 2026 | Apr 24, 2026 | SEC EDGAR |
| Annual report | 20-F | Dec 31, 2025 | Apr 23, 2026 | SEC EDGAR |
| Current report | 6-K | Mar 5, 2026 | Mar 5, 2026 | SEC EDGAR |
| Current report | 6-K | Feb 9, 2026 | Feb 9, 2026 | SEC EDGAR |
See a number that looks wrong?